{"schema_version":"secwatch.filing_event.v1","accession":"0000944809-22-000046","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.117570+00:00","generated_at":"2026-06-22T04:56:12.553380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OPKO Health reports Q3 net loss of $86.1M as COVID testing revenue collapses","bullets":["Consolidated revenue $179.7M, down 53% YoY from $385.8M, driven by lower COVID-19 testing.","Diagnostics revenue $142.8M (vs. $340.1M); BRL processed ~0.2M COVID PCR tests vs 2.2M last year.","Pharmaceuticals revenue $32.4M (vs. $36.9M); NGENLA royalties began; RAYALDEE sales $6.9M.","Operating loss $87.8M vs operating income $37.8M; net loss $0.11 per share vs $0.04 income.","BRL cut >$100M annualized costs; cash and equivalents $180.8M at Sept. 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000944809-22-000046","json":"https://secwatch.observer/filing/0000944809-22-000046.json","markdown":"https://secwatch.observer/filing/0000944809-22-000046.md","text":"https://secwatch.observer/filing/0000944809-22-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000094480922000046/0000944809-22-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000094480922000046/opk-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:56:12.553380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d1197462dcca36c3729c29d887944c49dc77784","claim":"OPKO HEALTH, INC. reported third quarter of 2022 results: revenue Consolidated total revenues for the third quarter of 2022 were $179.7 million, net income Net loss for the third quarter of 2022 was $86.1 million, EPS $0.11 per share.","evidence_excerpt":"Net loss for the third quarter of 2022 was $86.1 million, or $0.11 per share, compared with net income of $28.7 million, or $0.04 per diluted share, for the 2021 quarter.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/944809/000094480922000046/0000944809-22-000046-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2022"},{"label":"Revenue","value":"Consolidated total revenues for the third quarter of 2022 were $179.7 million"},{"label":"Net income","value":"Net loss for the third quarter of 2022 was $86.1 million"},{"label":"EPS","value":"$0.11 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}